Shenzhen Kangtai Biological Products Co., Ltd.
SZSE:300601.SZ
28.75 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,651.716 | 3,477.439 | 3,157.402 | 3,652.095 | 2,261.177 | 1,943.332 | 2,016.903 | 1,161.176 | 551.941 | 452.742 | 303.364 | 250.513 | 122.499 |
| Cost of Revenue
| 477.417 | 655.295 | 499.947 | 986.428 | 226.306 | 163.674 | 179.413 | 136.335 | 118.293 | 165.462 | 96.606 | 77.921 | 30.162 |
| Gross Profit
| 2,174.298 | 2,822.144 | 2,657.454 | 2,665.667 | 2,034.871 | 1,779.658 | 1,837.49 | 1,024.841 | 433.647 | 287.28 | 206.758 | 172.593 | 92.337 |
| Gross Profit Ratio
| 0.82 | 0.812 | 0.842 | 0.73 | 0.9 | 0.916 | 0.911 | 0.883 | 0.786 | 0.635 | 0.682 | 0.689 | 0.754 |
| Reseach & Development Expenses
| 508.123 | 500.749 | 801.857 | 354.264 | 267.061 | 198.261 | 177.823 | 84.736 | 39.533 | 48.263 | 45.745 | 36.463 | 18.987 |
| General & Administrative Expenses
| 104.65 | 128.972 | 58.198 | 65.508 | 35.428 | 31.477 | 41.258 | 35.702 | 24.397 | 17.388 | 18.344 | 28.475 | 55.595 |
| Selling & Marketing Expenses
| 843.979 | 1,192.956 | 1,086.36 | 578.239 | 878.407 | 784.574 | 1,005.331 | 615.419 | 219.736 | 102.821 | 40.862 | 57.104 | 50.784 |
| SG&A
| 948.629 | 1,517.512 | 1,144.558 | 643.747 | 913.835 | 816.052 | 1,046.589 | 651.121 | 244.133 | 120.209 | 59.205 | 85.579 | 106.379 |
| Other Expenses
| 536.322 | -145.033 | 74.409 | 73.925 | 110.474 | 92.985 | 7.829 | -4.177 | 13.619 | 2.299 | -1.367 | 34.014 | 42.79 |
| Operating Expenses
| 1,993.074 | 1,873.228 | 2,020.824 | 1,071.936 | 1,291.369 | 1,107.297 | 1,325.212 | 759.516 | 324.556 | 207.951 | 144.422 | 159.731 | 107.586 |
| Operating Income
| 181.224 | 948.916 | 747.025 | 1,452.245 | 775.371 | 657.817 | 481.259 | 242.162 | 85.679 | 69.158 | 35.977 | -33.968 | -28.274 |
| Operating Income Ratio
| 0.068 | 0.273 | 0.237 | 0.398 | 0.343 | 0.338 | 0.239 | 0.209 | 0.155 | 0.153 | 0.119 | -0.136 | -0.231 |
| Total Other Income Expenses Net
| -31.287 | -8.597 | -1,085.272 | -13 | -2.961 | 5.632 | 7.829 | -4.177 | 13.301 | 1.934 | -1.509 | 33.889 | 42.788 |
| Income Before Tax
| 149.937 | 940.32 | -338.246 | 1,439.245 | 772.41 | 663.449 | 489.089 | 237.985 | 98.98 | 71.092 | 34.469 | -0.078 | 14.514 |
| Income Before Tax Ratio
| 0.057 | 0.27 | -0.107 | 0.394 | 0.342 | 0.341 | 0.242 | 0.205 | 0.179 | 0.157 | 0.114 | -0 | 0.118 |
| Income Tax Expense
| -51.617 | 79.016 | -205.539 | 175.868 | 93.224 | 88.943 | 53.404 | 23.281 | 12.767 | 8.27 | 3.306 | -1.589 | 3.066 |
| Net Income
| 201.652 | 861.304 | -132.708 | 1,263.377 | 679.186 | 574.506 | 435.685 | 214.703 | 86.214 | 62.822 | 31.163 | 1.511 | 11.448 |
| Net Income Ratio
| 0.076 | 0.248 | -0.042 | 0.346 | 0.3 | 0.296 | 0.216 | 0.185 | 0.156 | 0.139 | 0.103 | 0.006 | 0.093 |
| EPS
| 0.18 | 0.77 | -0.12 | 1.16 | 0.64 | 0.57 | 0.44 | 0.22 | 0.096 | 0.071 | 0.038 | 0.002 | 0.013 |
| EPS Diluted
| 0.18 | 0.77 | -0.12 | 1.14 | 0.63 | 0.56 | 0.44 | 0.22 | 0.096 | 0.071 | 0.038 | 0.002 | 0.013 |
| EBITDA
| 627.941 | 1,295.098 | 0.443 | 1,898.467 | 881.553 | 756.755 | 572.241 | 301.34 | 150.878 | 124.209 | 103.652 | 66.926 | 17.481 |
| EBITDA Ratio
| 0.237 | 0.372 | 0 | 0.52 | 0.39 | 0.389 | 0.284 | 0.26 | 0.273 | 0.274 | 0.342 | 0.267 | 0.143 |